Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

SGMO Deferred Revenue (Non-current)

Payments received for goods or services the company will deliver after more than one year.

Sangamo Therapeutics, Inc.NASDAQ: SGMO

Deferred Revenue (Non-current) · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue (non-current) broadly unchanged from a year ago

Deferred revenue (non-current) stood at $5.87M at the end of Q1 FY2026, up 0.0% from a year earlier. Over 3 fiscal years it compounded at -62.3% a year.

Context

  • Deferred revenue (non-current) amounted to 9.8% of total assets at the end of Q1 FY2026, up 3.0 pp from a year earlier.
  • Deferred revenue (non-current) increased in 1 of the last 3 fiscal years.

What to watch

Whether deferred revenue (non-current) keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.87M— QoQ
Last fiscal yearDec 2025
$5.87M+0.0% YoY
Year agoMar 2025
$5.87M+0.0% since
Deferred Revenue (Non-current) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year+0.0%——
3-year CAGR-62.3%——
5-year CAGR——
10-year CAGR——

Deferred Revenue (Non-current) history

USD · from the balance sheet

Latest · FY2025
5.87M USD
Year-over-year change
+0.0%
4-year CAGR
-56.7%

Deferred Revenue (Non-current) vs competitors

How SGMO compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred revenue (non-current) is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +0.0% is the highest of 4, against a peer median of -38.5%.
  • Deferred revenue (non-current) amounts to 9.8% of total assets for SGMO, versus a peer median of 0.0%.
SGMO Competitors
Deferred Revenue (Non-current) for SGMO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CCCCC4 Therapeutics, Inc.Mar 2026$15.44M USD-38.5%-2.1%4.7%
SGMOSangamo Therapeutics, Inc.Mar 2026$5.87M USD+0.0%-62.3%9.8%
CDXSCodexis, Inc.Mar 2026$350K USD-28.6%-72.3%0.3%
OABIOmniAb, Inc.Mar 2026$0 USD——0.0%
ARMPArmata Pharmaceuticals, Inc.Mar 2026$0 USD——0.0%
IPHAInnate Pharma S.A.Dec 2025€0 EUR-100.0%—0.0%
MOLNMolecular Partners AGMar 2026CHF 0 CHF——0.0%
IMDXInsight Molecular Diagnostics Inc.Mar 2026$0 USD——0.0%
IVVDInvivyd, Inc.Mar 2026$0 USD——0.0%
MISTMilestone Pharmaceuticals Inc.Mar 2026$0 USD——0.0%
RANIRani Therapeutics Holdings, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding SGMO) —-38.5%-37.2%0.0%

Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents178.87M100.44M45.2M41.92M20.95M
Short-term Investments197.68M177.19M35.8M00
Net Receivables6.36M4.47M4.07M4.6M10.51M
Inventory00000
Other Current Assets009.26M5.18M4.37M
Total Current Assets398.77M300.33M94.33M51.69M35.83M
Property, Plant & Equipment (Net)124.7M125.53M52.87M34.76M14.11M
Goodwill39.7M37.55M000
Intangible Assets53.76M50.73M000
Long-term Investments88.17M29.85M1.5M1.5M0
Tax Assets06.27M000
Other Non-current Assets16.82M12.25M16.63M13.69M9.81M
Total Non-current Assets323.15M262.18M70.99M49.94M23.92M
Total Assets721.92M562.51M165.32M101.64M59.75M
Account Payables9.76M22.42M15.26M15.49M14.44M
Short-term Debt00000
Tax Payables0004.07M10.14M
Deferred Revenue85.71M51.78M07.56M899K
Other Current Liabilities20.84M11.89M11.73M14.57M17.72M
Total Current Liabilities127.89M111.71M47.73M45.81M42.47M
Long-term Debt00000
Deferred Tax Liabilities6.65M6.27M000
Deferred Revenue (Non-current)166.78M109.38M05.87M5.87M
Other Non-current Liabilities1.22M1.21M1.19M933K580K
Total Non-current Liabilities218.69M155.84M34.7M33.06M31.55M
Total Liabilities346.58M267.55M82.43M78.87M74.01M
Common Stock1.46M1.67M1.78M2.13M3.51M
Retained Earnings(956.27M)(1.15B)(1.41B)(1.5B)(1.63B)
Accumulated OCI(3.99M)(8.4M)(4.6M)(7.53M)(1.46M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity375.34M294.96M82.89M22.77M(14.27M)
Total Debt48.08M43.11M38.1M30.57M26.8M
Net Debt(130.79M)(57.34M)(7.1M)(11.35M)5.85M

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Intrinsic Alpha fair value

Locked

Current Price

$0.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.